Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford is part of a new international research network to investigate the interactions between the biology of the body's internal clock and the disordered physiological processes associated with stroke.

The five-year funding, totalling US$7M, has been awarded by the Leducq Foundation as part of its International Networks of Excellence Programme. The aim of this programme is to bring together teams of researchers from around the world with complementary expertise and resources. They will work to generate new knowledge with the potential to advance the diagnosis, prevention, and treatment of cardiovascular and neurovascular disease.

The work is due to start on 1 January 2022, with the European part of the network coordinated by Professor Alastair Buchan from the University of Oxford's Radcliffe Department of Medicine (RDM). He will work closely with Professor Russell Foster from the Sleep and Circadian Neuroscience Institute in the Nuffield Department of Clinical Neurosciences and Professor David Ray from the Oxford Centre for Diabetes, Endocrinology and Metabolism (RDM). Other participating institutions include the University of Munich, Stanford University, Harvard University, University of California, Los Angeles, and the Carlos III Health Institute and Hosptial 12 Octubre in Madrid.

The network aims to identify novel targets for stroke therapy based on circadian biology. Researchers will achieve this by defining circadian mechanisms at the brain-vascular interface, and immune, cardiovascular and metabolic systems in experimental stroke models. They will confirm and extend findings in cell and animal models with genetic, imaging, outcome, and biomarker analyses in stroke patients.

This trans-Atlantic network brings together basic, translational and clinical scientists with inter-disciplinary expertise in molecular biology, neurobiology, immunology, cardiovascular biology, circadian biology, imaging, genetics, biomarkers and clinical trials. The network will mentor and develop early career scientists through an exchange of Leducq fellows between labs, a journal club and annual summer schools. This network is uniquely positioned to discover new science, change the way stroke research is conducted, and train the next generation of stroke scientists for inter-disciplinary and translational research.

Similar stories

Evaluating risk to people with epilepsy during the COVID-19 pandemic - study wins international prize

In May 2020 our researchers initiated a global project to investigate how COVID-19 has affected people with epilepsy, their carers and health care workers.

New European initiative to accelerate the discovery and validation of biomarkers for neurodegenerative diseases

Members of the European Platform for Neurodegenerative Diseases (EPND) will establish a collaborative platform for efficient sample and data sharing, linking existing European research infrastructures to accelerate the discovery of biomarkers, new diagnostics and treatments for the benefit of people with neurodegenerative diseases such as Alzheimer's and Parkinson's.

COVID-19 infection has greater risk than vaccines of causing very rare neurological events

Research reveals risks of developing neurological complications following a positive COVID-19 PCR test, or a first dose of either the Oxford-AstraZeneca or Pfizer-BioNTech COVID-19 vaccinations.

Mapping uncharted networks in the progression of Parkinson’s

A major new $9 million project funded by the Aligning Science Across Parkinson’s (ASAP) initiative will map the original circuits vulnerable to Parkinson’s on an unprecedented scale. The project is a collaboration between core investigators Stephanie Cragg, Richard Wade-Martins, and Peter Magill at Oxford, Mark Howe at Boston University and Dinos Meletis at the Karolinska Institutet, as well as collaborators Yulong Li at Peking University and Michael Lin at Stanford University.

New genetic diagnosis technology for eye disease receives major funding award

Eye2Gene explores the use of AI to determine which genetic condition is causing a patient’s inherited retinal disease, by examining eye scans.